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Abstract
Background: Improved therapeutics aimed at ameliorating the devastating effects of neurodegenerative diseases,
such as Alzheimer’s disease (AD), are pertinent to help attenuate their growing prevalence worldwide. One
promising avenue for such therapeutics lies in botanical medicines that have been efficaciously employed
in the likes of traditional medicine doctrines for millennium. Integral to this approach is the necessity of
neuritogenesis and/or neuroprotection to counterbalance the deleterious effects of amyloid-β (Aβ) proteins.
Senegenin, a principle saponin of Polygala tenuifolia Willd., which has empirically shown to improve cognition
and intelligence, was chosen to evaluate its cytoprotective potential and possible neuritogenic and neuroprotective
effects.
Methods: The purpose of the present study was then to analyze morphological changes in neurite development
and altered protein expression of two proteins requisite to neuritogenesis, growth associated protein 43 (Gap-43)
and microtubule-associated protein 2 (MAP2) in PC 12 cells. Neuritogenic analysis was conducted with
immunofluorescence after incubation with Aβ (25–35) peptide, and to deduce information on cell viability and
mitochondrial functionality MTT (3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) was employed.
Results: This study found that cells pre-incubated with senegenin for 24 h (40 μg and 20 μg/ml) before
introducing Aβ attenuated Aβ-cytotoxicity, and significantly increased cell viability by 23 % and 34 % (P < 0.001),
respectively. In neurite outgrowth experiments, Aβ was compared to NGF positive control and senegenin treated
groups which showed a drastic decrease in the quantity, average length and maximum length of neurites (P < 0.001).
At concentrations of 1 μg/ml (P < 0.01) and 5 μg/ml (P < 0.05) senegenin triggered neuritogenesis with significant
increases in total neurite number, average length and maximum length. This was additionally shown through the
augmented expression of MAP2 and Gap-43.
Conclusions: These results suggest that senegenin possesses cytoprotective properties, can moderate neurite
outgrowth and augment MAP2 and Gap-43, thus suggesting a potential therapeutic value for Polygala tenuifolia in
neurodegenerative disorders.
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Background
A major factor precipitating the pathogenesis of neuro-
degenerative illnesses such as Alzheimer’s and Parkin-
son’s disease is misfolded proteins, particularly amyloids.
Neurons are highly susceptible to the deleterious effects
of misfolded proteins which are prone to aggregate when
large accumulations arise [1]. The pernicious effects
of amyloid-β (Aβ) constitute one of the hallmarks of
Alzheimer’s disease (AD). Alzheimer’s disease, a progres-
sive neurodegenerative illness, characteristically results
in severe cognitive deficits. The progressive cognitive
decline associated with AD is attributable to dystrophic
neurites and neuronal atrophy, which are the corollaries
of extracellular amyloid-β peptide (Aβ) deposition and the
intracellular deposition of neurofibrillary tangles (NFT)
[2]; the latter of which is comprised of hyperphosphory-
lated tau proteins, and posited to be the resultant effect of
the toxic cascade initiated by Aβ. The neurotoxic proper-
ties of Aβ have thus been formulated in an amyloid
cascade hypothesis which posits that aggregates of Aβ 42
accumulate into senile plaques, either triggering comple-
ment factors and cytokines or directly leading to synaptic
degeneration bypassing the activation of complement
factors and cytokines, continually proceeding to alter ionic
homeostasis and kinase activity. Ultimately, progressive
neuritic dysfunction, cell death and neurotransmitter defi-
cits result [3]. Current postulates, however, now strongly
support the notion that the initial memory loss seen in
AD directly correlates to oligomeric forms of Aβ, which
precipitate synaptic deterioration [4–7]. Therefore, with
the incidence of AD, the most common form of dementia,
steadily on the rise, and a global prevalence predicted to
affect over 80 million people by 2040 [8], the development
of efficacious therapeutics aimed at abating AD pathogen-
esis, most notably neuritic and synaptic regeneration, is a
necessity. Deciphering the complexities of AD stands at
the forefront of neuroscience, with extensive research
efforts demonstrating that Aβ is neuro-and synapto-toxic
in both in vitro and in vivo experiments. Various research
models have employed the use of the Aβ (25–35) peptide,
which retains the toxic properties of the full length
peptide (39–43), to test the pathogenic mechanisms of
Aβ, making it a desirable model for testing AD, and thus
chosen for the present study to examine its toxicity in a
neuronal cell line.
The PC 12 cell line, originally obtained from a trans-
plantable rat pheochromocytoma [9], has become a widely
used neuronal model to test neurotoxins implicated in
neurodegenerative disorders, notably Aβ. It has addition-
ally proven to be advantageous in expanding current
understandings of what cellular proteins/mechanisms
drive neurite growth. In the presence of neurotrophic fac-
tors, namely nerve growth factor (NGF), PC 12 cells cease
division, and differentiate into sympathetic-like neurons
producing long neurites [9, 10]. Upon differentiation PC
12 cells begin to express several integral proteins respon-
sible for neurite growth [11, 12]. Growth associated pro-
tein 43 (Gap-43), a major polypeptide localized in the
growth cone [13], is required for growing neuronal pro-
cesses during development and regeneration [14]. Induc-
tion of Gap-43 by NGF has been reported to take place
within 24 h, and is a prerequisite of neurite outgrowth in
PC 12 cells [15]. Gap-43 is thus an essential protein im-
perative to the various stages underlying neural plasticity
with a strong correlation to the growth phase of neu-
rons, making it a good indicator of regeneration.
Moreover, plasticity alterations in the brain evidently
require the polymerization of microtubules, which
play a paramount role in neuronal growth processes [16,
17], and intracellular signaling, with an integral relation-
ship to MAPs that are mobilized during dentritic and
axonal development. Microtubule-associated proteins
(MAPs) regulate tubulin polymerization and are cardinal
in microtubule assembly [11]. MAP2 shares a reciprocal
relationship with mitogen-activated protein kinases
(MAPKs) by being a cognate substrate. MAPKs NGF-
stimulated activities and its association with phosphoryl-
ation states putative to neuritogenesis [18, 19] illustrate
that MAPK is a pertinent cellular component of MAP2
function. Induction of neurite growth in PC 12 cells ap-
pears to be dependent upon the activation of MAPK, in
that the inhibition of MAP kinase completely blocks
NGF-induced neurite growth. Similarly, brief activation of
MAP kinase by other growth factors has been shown to
result in reduced PC 12 differentiation [20]. Not surpris-
ingly, PC 12 neurite outgrowth requires similar intracellu-
lar mechanisms as hippocampal neurons, for instance,
those that drive microtubule assembly and trigger MAPs
[17, 21]. Another indispensable component of neuronal
functionality, and imperative for neuritic regeneration,
is the requisite synaptic terminal and its vesicles, both
of which are additionally expressed PC 12 cells [22].
A novel approach to tackling the complexities of
neurodegenerative disorders lies in the plasticity of the
brain, which undergoes continued functional and struc-
tural alterations throughout life [23, 24]. Extensive re-
search has shown that long after postnatal development
the brain continues to birth new neurons (neurogenesis),
primarily in the dentate gyrus of the hippocampus
[25, 26], a structure well known for memory process-
ing. Influential factors that contribute to neural plasticity
are continuously being elucidated, with paramount im-
portance being the natural, endogenous structural adapta-
tions induced through neurotrophins. To date, various
neurotrophins, including NGF, have proven to be effica-
cious in increasing synaptic efficacy, promoting neurito-
genesis, synaptogenesis, and neuronal survival [27–30].
The use of neurotrophins as therapeutic agents, however,
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is limited since due to their molecular structure they
don’t readily cross the blood brain barrier [31–34].
Therefore, exogenous substances that either trigger
neurotrophins or independently contribute directly or
indirectly through intracellular signaling mechanisms
to neurito-and-synaptogenesis are likely to be an essential
element of future therapeutics that halt neurodegenera-
tion. Numerous plant sources have congruently been
shown to possess nootropic activity and promote func-
tional and structural changes in various cell types.
The root of Polygala tenuifolia Willd. has been used
for more than a millennia in traditional Chinese medi-
cine for the treatment of memory loss associated with
aging, forgetfulness and amnesia. Several of the most
commonly used empirical traditional Chinese medicine
formulas aimed at improving cognition contain Polygala
tenuifolia [35]. Biochemical analysis has ascertained that
the active components of P. tenuifolia are primarily sapo-
nins that are derivatives of presenegenin. Current research
efforts directed towards elucidating the therapeutics
of P. tenuifolia have shown that it possesses both
neuroprotective and nootropic activity, exemplified in
its ability to effectively attenuate scopolamine-induced
memory impairments [36, 37], decrease Aβ secretion
[38, 39], up regulate neurotransmitters [40], and in-
crease NGF secretion is cultured astrocytes [41]. In
addition, P. tenuifolia has been shown to promote the
proliferation of hippocampal stem cells and neurite
outgrowth [42], demonstrating that it’s a promising
agent in the amelioration of neurodegeneration. There-
fore, the aim of this research was to explore the potential
neuroprotective and neuritogenic properties of senegenin
(Fig. 1), a component of P. tenuifolia root extracts,
on Aβ (25–35)-induced cyto-and-neurito-toxicity in dif-
ferentiated PC 12 cells.
Methods
Materials
Aβ (25–35) peptide fragment, poly-D-lysine, and 3-(4,5-
dimethylthioazol-2-yl) 2,5 diphenyltetrazolium bromide
(MTT) were all obtained from Sigma Chemical Co., (St.
Louis, USA). Dimethyl sulfoxide (DMSO) was purchased
from AMRESCO, (Solon, OH, USA). Mouse β-NGF was
purchased from PeproTech Asia, (Rehovot, Israel). All tis-
sue culture agents were purchased from Thermo Scientific
Hyclone (Utah, USA). Senegenin - CAS No.667438-01-9,
> 98 %HPLC) was obtained from Mansite Pharmaceutical
Co., LTD. (Chengdu, China).
Cell culture
PC 12 cells were obtained from Shanghai Institute for
Biological Science Cell Bank, CAS, (Shanghai, China)
and maintained in high glucose Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 5 % (v/v)
heat-inactivated horse serum, 5 % (v/v) heat-inactivated
fetal bovine serum, a mixture of 1 % penicillin/strepto-
mycin and incubated in an atmosphere with 5 % CO2/
95 % humidified air at 37 °C. Cells were kept in 25 cm2
cell culture flasks (Corning Incorporated, USA) and
dissociated every 3–4 days. Prior to all treatments cells
were plated on either poly-D-lysine-coated 96-well mi-
croplates (Corning Incorporated, USA) or 1.8 cm2 glass
cover slips to facilitate PC 12 differentiation. PC 12 cell
differentiation was induced with differentiating medium
(DM) which was comprised of DMEM, 1 % donar equine
serum, 1 % penicillin/streptomycin, and 100 ng/ml mouse
β-NGF. Every 3–4 days half of the differentiating medium
was changed and replaced with fresh DM. All cells tested
in this experiment underwent differentiation prior to
evaluation.
Cell viability assay
Cell viability was determined by MTT (3,(4,5-dimethyl-
thiazol-2-yl)2,5-diphenyltetrazolium bromide) to provide
information on cell viability and mitochondrial function-
ality. Cells were seeded at a density of 1 × 104 in 100 μl
DM (NGF 100 ng/ml) onto 96-well poly-D-lysine-coated
plates for 4 days to facilitate neurite growth. After 4 days,
cells were pre-treated with or without senegenin for
24 h, followed by incubation with Aβ (25–35) peptide for
another 24 h. Prior to use, Aβ (25–35) was incubated at
37 °C for 4 days to allow aggregation. After incubating
MTT (20 μl) for 4 h at 37 °C the formazan crystals were
lysed in 150 μl dimethyl sulfoxide (DMSO), and the
microplates were shaken vigorously to ensure complete
solubilization. The optical density was 584 nm and read/
determined in a Miltiskan MK 3 reader (Thermo Lab
Systems Beverly, MA, USA). All values were presented
as means ± SEM of numbers obtained from 6 wells,
from 3 separate experiments, and cell viability (%)
Fig. 1 Chemical structure of Senegenin
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was expressed as a percentage relative to the NGF-
treated control cells.
PC12 neurite outgrowth experiments
Coated 18 × 18 mm coverslips pretreated with poly-D-
lysine were placed into six-well culture plates and PC 12
cells were then plated at a density of 1.4–1.6 × 104 in
1.5 ml cell suspension per well in the presence of DM to
allow for differentiation. The plates were maintained in a
homeostatic environment (see above) and half of the
DM was changed every 3–4 days. Upon 7 days of differ-
entiation, Aβ (10 μM) was added for 4 days to measure
the effects of neuritic degeneration. Subsequently, 4 days
after Aβ treatment the medium was removed and replaced
with fresh medium containing NGF with or without vari-
ous concentrations of senegenin to measure potential
neurite regeneration. Moreover, the application of neurite
specific antibodies (GAP-43 (1:100), MAP2 (1:50)), were
used as markers of neurite growth formation, respectively.
For this study, neurites were defined as processes nothing
less than 10 μm or equal to the diameter of the cell body.
Morphological observation of neurite outgrowth was char-
acterized by three different parameters: average neurite
length, maximum neurite length and neurite quantity.
Neurite outgrowth parameters were quantified by visual
counting and manual tracing, and acquired through
confocal microscopy.
Immunfluorescence
Cells were plated at a density of 1.4–1.6 × 104 on poly-D-
lysine-coated 18 × 18 mm coverslips in six-well culture
plates (1.5 ml cell suspension per well). Differentiated cells
were fixed in paraformaldehyde for 15 min at room
temperature, succeeded by 10 min fixation with ice cold
acetone at −20 °C, followed by several rinses with PBS.
Non-specific binding in 5 % goat serum and 0.2 % Triton
X-100 (BioSource Invitrogen, Carlsbad, CA, USA) pre-
ceded incubation with antibodies against Gap-43, and
MAP2 (Neomarkers, Fremont, CA, USA) for 1 h at 37 °C.
After a series of washes with PBS-0.05 % Triton X-100, a
secondary antibody conjugated to FITC (ZyMed, San
Fransisco, CA, USA), was applied and just prior to micro-
scopic examination the cell nuclei were stained with 4′-6-
diamidino-2-phenylindole (DAPI). All slide images were
acquired by using a Nikon Ti 200 laser scanning confocal
microscope.
Statistical analysis
The data were expressed as means ± S.E.M. One way
ANOVA followed by the LSD post hoc test was done
for multiple group comparisons of the data collected.
P values < 0.05 were considered statistically significant.
Statistical analysis was performed using SPSS 17.0.
Results
The effects of senegenin on Aβ-induced cytotoxicity of PC
12 cells
MTT was used to determine the effects of senegenin
on the cell viability of PC 12 cells after Aβ-induced
cytotoxicity. Following a 24 h incubation period with
10 μM Aβ (25–35) cell viability was significantly reduced
(Fig. 2) compared with control. Cells pre-incubated with
senegenin for 24 h before introducing Aβ significantly
increased cell viability, in dose-dependent manners as
previously described [43]. When administered at con-
centrations of 40 μg/ml and 20 μg/ml senegenin signifi-
cantly attenuated Aβ cytotoxicity (Fig. 2), increasing cell
viability 23 % and 34 %, respectively. These results demon-
strate the cytoprotective capabilities of senegenin against
Aβ cytotoxicity. In addition, ginsenoside Rg1 attenuated
cytotoxicity up to 21 % (data not shown). Comparatively,
this shows that senegenin offers greater cellular pro-
tection than Rg1, a commonly employed derivative
(ginsenoside) of Panax ginseng that has shown to ef-
fectively attenuate Aβ-induced cytotoxicity in numerous
experiments [44–46].
Morphological observation of senegenin neurite
protection upon NGF removal
Observational analysis conducted by microscope con-
firmed that senegenin can protect neurites of differenti-
ated PC 12 cells from the removal of NGF (reverting from
DM back to culture medium). Cells grown for 10 days in
DM showed long neuritic outgrowth (Fig. 3a); however,
subsequent removal of NGF lead to retraction of neurites.
48 h after the removal of NGF differentiated PC 12 cells
retrogressed to the proliferating stage with substantial cell
clumping, and fragmented and atrophied neurites (Fig. 3b).
Fig. 2 Effects of senegenin on MTT levels in Aβ-induced cytotoxicity in
PC 12 cells. The cells were incubated for 24 h at 37 °C in the absence
(Control & Aβ) or in the presence of senegenin (concentrations of
20 μg/ml & 40 μg/ml), and then incubated for 24 h followed by
incubation with Aβ for 24 h. The data are the means ± S.E.M. of three
separate experiments performed in triplicate. Cell viability (%) was
expressed as a percentage relative to the NGF-treated control.
*P < 0.001 vs. Amyloid-β treatment group
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Cells that were treated with senegenin (5 μg/ml) retained
greater neurite distribution, length and number (Fig. 3c, d);
thus, morphologically demonstrating the neuroprotective
efficacy of senegenin on neurites.
Neuritogenic efficacy of senegenin in Aβ-induced neuritic
degeneration
PC 12 cells were cultured in the presence of 100 ng/ml
β-NGF for 7 days to allow for significant differentiation
(neurite outgrowth). After 7 days, half of the medium
was changed which included the introduction of 10 μm
Aβ (25–35) into the DM for 4 days. Following 4 days of
incubation differentiated PC 12 cells were fixed and
labeled with primary antibodies for Gap-43 and MAP2
as neurite growth markers. Aβ drastically decreased total
Gap-43 neurite values (P < 0.001), quantity 50 % of con-
trol, average length 41 % of control, and maximum
length 65 % of control, (see Figs. 4a and 5a-b). Moreover,
Aβ reduced MAP2 neurite values (P < 0.001) quantity
38 % of NGF positive control, average length 56 % of con-
trol and maximum length 35 % of control (see Figs. 4b
and 5c-d), showing that Aβ (25–35) induced significant
neuritic atrophy.
Thereafter, the neuritogenic effect of senegenin in PC
12 cells was explored. PC 12 cells were grown in DM for
7 days, after which Aβ (25–35) was introduced into the
medium for an additional 4 days. Next, the medium was
removed and replaced with fresh medium (DM) with or
without (only NGF100 ng/ml) the presence of senegenin
(1 μg & 5 μg/ml). The doses were chosen as a mean
variance in reference to similar experimental results
[47]. After 4 days treatment the cells were fixed and
immunostained with Gap-43 and MAP2 as neuritic
markers. The total quantity, average length, and max-
imum lengths were measured against Aβ (25–35) control
with marked decreases in Aβ-treated cells (see Figs. 4c-e
and 5b, d). Treatment with senegenin significantly in-
creased neurite outgrowth/regeneration in PC 12 cells in
a concentration-dependent manner (P ≤ 0.01) Table 1.
At concentrations exceeding 10 μg/ml senegenin did not
significantly increase neuritogenesis (data not shown).
Whereas, at concentrations of 1 μg/ml (P < 0.01) and
5 μg/ml (P < 0.05) senegenin triggered neuritogenesis
showing marked increases in total neurite number,
average length and maximum length (see Figs. 4c-d and
5e-f, i). Notably, the use of NGF alone to trigger regen-
eration after administration of Aβ did not significantly
regenerate neurites compared to senegenin treatment or
Aβ control (Figs. 4c-e, 5g, h). The use of NGF has
shown to induce neurite growth in cortical neurons
and PC 12 cells so its neuritogenic efficacy was mea-
sured against dose-dependent concentrations of senegenin
Fig. 3 Morphological examination of PC 12 cells with or without senegenin. a represents PC 12 cells after 7 days incubation with DM (NGF
100 ng/ml). 48 h after the removal of DM, PC 12 cells loose neuritic processes and begin to proliferate (b). After the removal of DM, 5 μg/ml
senegenin was added to the well. Morphological examination shows decreased axonal atrophy suggesting a neuroprotective effect (c). d illustrates
retained neurite growth in the presence of 5 μg/ml senegenin 48 h after removal of DM
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wherein, of the concentrations utilized, it showed that
1 μg/ml (Fig. 4e) was the most effectual (P < 0.05)
(Table 1).
Discussion
Severe neuronal atrophy with neuritic degeneration is a
common pathogenic characteristic of neurodegenerative
disorders. The possibility of regeneration presents to be of
cardinal significance in abating neurodegeneration. To date,
in vivo and in vitro experiments have demonstrated that
axonal, dendritic and synaptic regeneration are possible
[42, 46, 48–50]. One postulate that facilitates the regener-
ation of neuronal structures is the intracellular signaling
proteins attributable to neural plasticity; possibilities that
Fig. 4 a The variance between the expression of Gap-43 positive neurites in NGF positive controlled growth and Aβ-induced toxicity. After
7 days of growth cells were treated with or without 10 μm Aβ (25–35) for 4 days and then fixed and marked with Gap-43 and examined by
immunofluorescence. In the absence of Aβ, neurites retain optimal growth and higher cell differentiation. *P < 0.001 vs. amyloid-β treatment
group. b The variance between the expression of MAP2 positive neurites in NGF positive controlled growth and Aβ-induced toxicity following
the same protocol as above (see a). In the absence of Aβ neurites retain optimal growth and higher cell differentiation. *P < 0.001 vs. amyloid-β
treatment group. c The variance between the expression of MAP2 positive neurites in NGF and senegenin treated groups after Aβ-induced
atrophy. After 7 days of growth cells were treated with or without 10 μm Aβ (25–35) for 4 days. Subsequently, NGF and senegenin were introduced
for an additional 4 days to incite regeneration. Next, the cells were fixed and marked with MAP2 and examined by immunofluorescence. In the
presence of senegenin neurites expressed a higher protein level and a more significant outgrowth. **P < 0.01 vs. amyloid-β & NGF treatment groups.
*P < 0.05 vs. amyloid-β treatment group. *aP < 0.01 vs. amyloid-β treatment group. d The effects of senegenin on neuritogenesis after Aβ(25–35)-induced
atrophy. PC 12 cells were differentiated for 7 days in the presence of NGF and were then treated with or without Aβ. 4 days after incubation with Aβ
cells were treated with senegenin at concentrations of 1 μg & 5 μg/ml or NGF (100 ng/ml). Following an additional 4 days of treatment, the cells were
then fixed and immunostained for phosphorylated Gap-43 as a neurite marker. The quantity, average length and maximum lengths were measured
and compared. *aP < 0.05 vs. NGF treatment group. *bP < 0.05 vs. amyloid-β, NGF and 5 μg treatment groups. *cP < 0.01 vs. amyloid-β, NGF and 1 μg
treatment groups. e The differences in the efficacy of drug treatments aimed at neuritogenesis were measured following the protocol mentioned
above, with 1 μg/ml evincing a marked effect. *P < 0.05 vs. NGF treatment. * *P < 0.05 vs. 5 μg senegenin and NGF treatments
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may be innate to the mammalian brain, but are somewhat
repressed in the adult brain. Although under the influence
of nootropic agents and neurotrophins they may become
reactivated leading to neurito-and-synaptogenesis.
The aim of this present study was to evaluate the
cytoprotective and neuritogenic/regenerative potential
of senegenin. Cell viability, a valuable indication of mito-
chondrial function and integral to cellular differentiation,
Fig. 5 a-i displaying the effects of NGF, Aβ-induced neurite atrophy and neuritogenic outcomes of senegenin. a PC 12cells after 7 days of NGF-
induced neurite outgrowth with positive expression of Gap-43. b Aβ-induced axonal atrophy and cell loss with additional reduction in Gap-43
expression. PC 12 cells were differentiated in DM for 7 days, thereafter Aβ was administered for 4 days. c PC 12 cells immunostained with MAP2
7 days after NGF-induced differentiation. d PC 12 cells were differentiated in DM for 7 days with subsequent incubation in the presence of Aβ for
4 days, then immunostained with MAP2 as a neurite marker. e Neuritogenic effect of senegenin (5 μg/ml) after 4 days of Aβ-induced atrophy. PC
12 cells show increased neurite outgrowth and MAP2 expression. f Neuritogenic effect of senegenin (5 μg/ml) after 4 days of Aβ-induced atrophy.
PC 12 cells show increased neurite outgrowth and Gap-43 expression. g Neuritogenic effect of NGF (100 ng/ml) after 4 days of Aβ-induced atrophy.
PC 12 cells show little neurite outgrowth w/ MAP2 expression. h Neuritogenic effect of NGF (100 ng/ml) after 4 days of Aβ-induced atrophy. PC 12 cells
show moderate neurite outgrowth w/ Gap-43 expression. i Neuritogenic outcome in the presence of senegenin (1 μg/ml) after 4 days of Aβ-induced
atrophy. PC 12 cells show increased neurite outgrowth w/ Gap-43 expression
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signaling and growth [51] was chosen to test the neuro-
toxic properties of Aβ. Aβ (25–35), a commonly employed
neurotoxic peptide [52–55], decreased cell viability by
~60 %. Interestingly, senegenin, at dose-dependent con-
centrations (20 μg and 40 μg/ml), attenuated Aβ toxicity
and significantly increased cell viability in differentiated
PC 12 cells. Aβ-induced neurotoxicity is thought to be
partially caused by the induction of apoptotic pathways
[56] and proapoptotic factors such as reactive oxygen
species (ROS), endoplasmic reticulum (ER) stress and ni-
tric oxide (NO). Research has shown that Aβ targets the
apoptosis signal-regulating kinase 1 (ASK1) – JNK path-
way [57, 58] which, through the production of ROS,
constitutes a major apoptotic signaling pathway. In PC 12
cells, Aβ-induced cell death results from ROS-mediated
activation of ASK1, which is independent of the ER stress
pathway [57]. Caspase-2 has also been implicated in
the induction of Aβ-induced apoptotic cell death in
several neuronal populations including PC 12 [58]. In
addition, c-Jun N-terminal kinase (JNK), which is ac-
tivated by Aβ, plays a crucial role in triggering Fas
ligand death factors that in turn leads to the binding
of Fas ligand to its receptor Fas, and subsequently to
the activation of a caspase cascade [59]; thus support-
ing the implicated role of caspase-2 in apoptotic cell
death. Based on the activation of the JNK pathway
and the following cellular cascades induced by Aβ
one possible mechanism by which senegenin exhibits
its cytoprotective qualities is through inhibition of ASK1
and/or JNK pathways. Additional support for this postu-
late can be found in the prevention of apoptosis in NGF-
deprived PC 12 cells through inhibition of JNK or c-Jun
[59]. Although evidence supports this mechanism of ac-
tion further research is required to delineate the potential
relationship of senegenin and the JNK pathway.
The attributes of neural plasticity, which encompass
neuritogenesis, are proving to be a promising avenue of
exploration by elucidating the complexities of the neur-
onal framework; from which new therapeutic angles
have begun to arise. From this perspective, the neurito-
genic potential of senegenin was examined. Results
showed that at dose-dependent concentrations (1 μg and
5 μg/ml) neurite outgrowth/regeneration was potenti-
ated. The induction of neurite growth requires the
coordinate expression of certain growth proteins such as
Gap-43 and MAP2, both of which, in comparison to Aβ-
treated groups, were up-regulated after introduction of
senegenin. These results are in agreement with previous
studies that demonstrated that during times of regener-
ation Gap-43 expression rises, and is essential to neurite
formation where it is expressed in along the entire axon
[60, 61], with the progression of neuritogenesis shifting
the concentration of Gap-43 to more distal locations;
notably, growth cones and synaptic regions [61]. More-
over, in the absence of Gap-43 via the introduction of
anti-Gap-43 antibodies neuritogenesis is prevented [60].
Gap-43 is a phospho-protein and a major substrate of
protein kinase C (PKC), which implies that Gap-43 regu-
lation of growth cones relies on a correlative relationship
with PKC-induced phosphorylation [62, 63]. Further-
more, diacylglycerols (DAGs) an endogenous activator of
PKC has shown to induce neuritogenesis in ganglia
explants [64]. In concurrence with the relationship
between PKC, neurite outgrowth and Gap-43, one likely
mechanism of action for the neuritogenic efficacy of
senegenin is its possible stimulation of PKC, leading to
increased phosphorylation of Gap-43, and therefore to
the initiation of growth cone formation and enhanced
neurite outgrowth. This postulate is concordant with
Yankner et al. [65] results that demonstrated marked
acceleration in initial neurite growth and greater sen-
sitivity to NGF in PC 12 cells expressing higher levels
of Gap-43. PKC has additionally been found to phos-
phorylate MAP2, which is associated with decreased
Table 1 The changes in neurite composition under the influence of Aβ-induced degeneration and drug treatments
Treatments & protein expression Neurite quantity Average length Maximum length
NGF positive control w/ Gap-43 15.5 ± 2.38* 81.75 ± 15.33* 134.75 ± 22.91*
NGF positive control w/MAP2 10.5 ± 1.29* 68.75 ± 7.23* 139.0 ± 34.42*
Amyloid-β w/Gap-43 7.0 ± 1.83 41.0 ± 9.63 69.5 ± 21.25
NGF control w/MAP2 5.25 ± 0.957 48.0 ± 3.56 73.5 ± 8.18
Amyloid-β w/MAP2 4.0 ± 0.826 38.25 ± 11.44 49.25 ± 11.27
Senegenin 5 μg w/Gap-43 7.75 ± 1.71 46.5 ± 5.8 78.25 ± 17.35
Senegenin 5 μg w/MAP2 9.5 ± 2.38* 54.25 ± 7.04* 100.5 ± 24.15*
Senegenin 1 μg w/Gap-43 8.25 ± 1.71* 62.25 ± 8.06* 126.75 ± 36.86*
NGF treatment w/Gap-43 5.0 ± 3.56 45.0 ± 15.64 78.5 ± 36.74
Cells were grown for 7 days in the presence of DM, followed by 4 days incubation with Aβ (25–35) peptide. The medium was then changed to include various
concentrations of drugs for an additional 4 days to allow for neurite outgrowth. PC 12 cells were then fixed and labeled with primary antibodies
*P < 0.01 vs. Amyloid-β treatment group
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cytoskeletal stability [66]. Conversely, dephosphorylation
of MAP2 is predicted to have an inverse reaction, thereby
promoting cytoskeletal stabilization. Such a change in
phosphorylated states leads to the instability of microtu-
bules, which in turn corresponds with neurite outgrowth
in hippocampal neurons [67]. Previous studies have noted
that MAPs are imperative to cytoskeletal regulation and
neurite growth [17], especially in dendritic development
where MAP2 is heavily enriched [68] and goes through
various phosphorylated states [69] that are in part regu-
lated by PKC [66, 70]. From this, some reasonable infer-
ences can be made regarding senegenin’s mechanisms of
action. One, since MAP2 goes through alternating states
of phosphorylation inducing oscillations of stability within
microtubules, which allows for neuritic formation and
outgrowth the mobilization of MAPs must be integral to
the growth stage in PC 12 cells. Two, while the activation
of MAP2 is important for PC 12 differentiation there
appears to be little correlation between NGF and PKC-
induced phosphorylation of MAP2 [71], suggesting that
the activation of MAP2 is not a result of NGF-induced
activation of PKC. We then speculate that if senegenin
triggers PKC and phosphorylation of MAP2 this would
lead to a notable increase in neurite growth as demon-
strated in this study. Correspondingly, the increased
protein recognition of Gap-43 and MAP2 by immunfluor-
escence in differentiated PC 12 cells found in this experi-
ment is concordant with the associative mechanisms of
action and imperative roles that these proteins play in
neuritic development and formation.
While it is worth noting that the neurite outgrowth
elicited by senegenin may have been produced through
potentiating NGF-induced outgrowth, results demon-
strated that in the sole presence of senegenin (Fig. 3c-d)
neurite outgrowth was maintained. We thus propose
that the results elicited herein stemmed from senegenin’s
effects on PKC and phosphorylation of MAP2 rather
than potentiating NGF.
Conclusion
Dysfunctional protein assembly precipitates the occur-
rence of neurodegenerative illnesses like AD through
abnormal accumulation. A prototypical example is the
neurotoxic peptide Aβ. Two of most significant corollar-
ies of misfolded proteins are dystrophic neurites and
neuronal atrophy. This implies that to effectively tackle
neurodegenerative diseases desired therapeutics need to
possess neuroprotective and neuritogenic capacities. A
promising source of such potential therapeutics can be
found in botanical medicines. P. tenuifolia has empiric-
ally shown to be efficacious in treating cognitive disor-
ders, and was thus a fitting choice for exploration of
neuroprotective and neuritogenic potential. The results
generated in our study suggest that senegenin not only
possesses cytoprotective, and neuritogenic properties,
but that it can also augment the expression of cardinal
growth proteins vital to neural plasticity. One possible
mechanism by which senegenin exhibits its cytoprotec-
tive qualities is through inhibition of ASK1 and/or JNK
pathways. While deducing the exact neuritogenic mech-
anisms of action went outside of our studies aim,
concordant studies lead us to hypothesize that these re-
sults stemmed from senegenin’s activation of PKC and
its phosphorylation of MAP2. Although these results are
in agreement with other literature surrounding the
neuritogenic and neuroprotective nature of P. tenuifolia,
further research is required to elucidate senegenin’s
exact neurogenic mechanisms and its full therapeutic
range. All in all, these results continue to support and
illuminate P. tenuifolia’s (i.e., senegenin) salubrious po-
tential, and suggest it may be efficacious in the treat-
ment of neurodegenerative disorders.
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